COMMUNIQUÉS West-GlobeNewswire

Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Maple acquires Beyond ADHD to expand responsible ADHD and mental health care across Canada
05/11/2025
Acquisition strengthens access to clinically led virtual ADHD and mental health programs nationwide TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Maple, Canada’s leading virtual care company, today announced the [...]
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
05/11/2025
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market [...]
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
05/11/2025
RadNet subsidiary DeepHealth to commercialize a robust end-to-end remote-imaging offering featuring both TechLive™ remote scanning technology and Alpha RT’s MRI staffing services and training programs LOS ANGELES, Nov. [...]
Immuron IMM-529 IND approved by FDA
05/11/2025
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095) for the IMM-529 [...]
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
05/11/2025
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. [...]
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
05/11/2025
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL [...]
Santhera Closes USD 13 Million Royalty Monetization Agreement
05/11/2025
Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches [...]
Phonak announces global brand ambassador, Sara Mearns, the first-ever principal dancer with hearing loss at the New York City Ballet
05/11/2025
From Swan Lake to The Nutcracker, ballet star shares the reality of living and dancing with hearing loss STÄFA, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sara Mearns, the first principal dancer with hearing loss at [...]
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
05/11/2025
Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted [...]
LIfT BioSciences to present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer
05/11/2025
London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of [...]
AVEROA Receives UK MHRA Approval for XOANACYL®, an Oral Therapy Targeting Key Complications of Chronic Kidney Disease (CKD)
05/11/2025
The MHRA ( Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval (June 2025) [...]
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES
05/11/2025
TME PHARMA POURSUIT SA NOUVELLE STRATÉGIE D'INVESTISSEMENT ET SIGNE UNE LETTRE D'INTENTION AVEC UNE SOCIÉTÉ ALLEMANDE SPÉCIALISÉE DANS LES RESSOURCES NATURELLES Nouvelle étape vers la diversification des investissements [...]
TME Pharma advances its new investment strategy and signs LOI with German resources company
05/11/2025
TME Pharma advances its new investment strategy and signs LOI with German resources company A further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
05/11/2025
COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% [...]
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
05/11/2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug [...]
Pennant Acquires Senior Living Communities in Idaho and Wisconsin
05/11/2025
EAGLE, Idaho, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces two [...]
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
05/11/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SAFFRON, a [...]

Pages